Home Congress Hub

CG CONGRESS HUB

  • All
  • Posters
  • Presentations
  • Publications
SUO 2025 – TOPLINE RESULTS FROM BOND-003 COHORT P PODIUM
Topline Results from BOND-003 Cohort P- A Multi-National, Single-Arm Study of Intravesical Cretostimogene for Treatment of High-Risk, Papillary Only, BCG-UR NMIBC
SUO 2025 – FIRST RESULTS CORE-008 COHORT A PODIUM
First Results from CORE-008 Cohort A- Phase 2 Study of Intravesical Cretostimogene in Patients with High-Risk CBC-Naïve NMIBC
SUO 2025 – CRETO-EAP TIPS EPOSTER
Design and Implementation of a Patient-Centric Expanded Access Program with Cretostimogene in NMIBC Unresponsive to BCG
SUO 2025 – CORE-008 COHORT B TIPS EPOSTER
CORE-008 Cohort B: Evaluating Intravesical Cretostimogene in Patients with High-Risk, BCG-Exposed NMIBC
SUO 2025 – FINAL RESULTS BOND-003 COHORT C EPOSTER
Durable 24-Month Outcomes from BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene for High-Risk BCG-UR NMIBC with CIS
NCSAUA 2025- BOND-003 COHORT P PODIUM
BOND-003 Cohort P-A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of HR, Papillary-Only, BCG-UR NMIBC (pdf)
WSAUA 2025 – PIVOT-006 UNMODERATED POSTER
Ongoing Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Versus Surveillance for the Treatment of Intermediate-Risk NMIBC (pdf)
WSAUA 2025 – CRETO-EAP MODERATED POSTER
Streamlined, Patient-Centric Design of the Cretostimogene Expanded Access Program in Patients with NMIBC Unresponsive to BCG (pdf)
WSAUA 2025 – CORE-008 MODERATED POSTER
Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene in Patients with High-Risk NMIBC (pdf)
WSAUA 2025 – BOND-003 COHORT P MODERATED POSTER
First Results from BOND-003 Cohort P- A Multi-National, Single-Arm Study of Intravesical Cretostimogene for Treatment of High-Risk, Papillary Only, BCG-UR NMIBC (pdf)
WSAUA 2025 – BOND-003 COHORT C MODERATED POSTER
Final Results from BOND-003 Cohort C: A Phase 3, Single-Arm Study of Intravesical Cretostimogene for High-Risk BCG-UR NMIBC with CIS (pdf)
SIU 2025 – CRETO-EAP UNMODERATED POSTER
Streamlined, Patient-Centric Design of the Cretostimogene Expanded Access Program in Patients with NMIBC Unresponsive to BCG (pdf)
SIU 2025 – CORE-008 UNMODERATED POSTER
Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene in Patients with High-Risk NMIBC (pdf)
SIU 2025 – PIVOT-006 UNMODERATED POSTER
Trial In Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Versus Surveillance for the Treatment of Intermediate-Risk NMIBC (pdf)
SIU 2025- BOND-003 COHORT P MODERATED POSTER
Ongoing Trial: BOND-003 Cohort P- A Multi-National, Single-Arm Study of Intravesical Cretostimogene for Treatment of High-Risk, Papillary Only, BCG-UR NMIBC (pdf)
SIU 2025- BOND-003 COHORT C MODERATED POSTER
Encore Durability Results From BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene for High-Risk BCG-UR NMIBC with CIS (pdf)
NCSAUA 2025- BOND-003 COHORT C PODIUM
Encore Durability Results From BOND-003 Cohort C: Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for HR BCG-UR NMIBC with CIS (pdf)
NCSAUA 2025- PIVOT-006 PODIUM
PIVOT-006-A Phase-3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of IR NMIBC (pdf)
NCSAUA 2025- CORE-008 PODIUM
Updates to CORE-008: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with HR NMIBC (pdf)
SUNA 2025 – POSTER
Integrating Cretostimogene Grenadenorepvec in Urology Practices: Clinical and Practical Nursing Considerations from the BOND-003 Study (pdf)
NEAUA 2025 – PODIUM PRESENTATION
24-Month Durability From BOND-003 Cohort C in Patients with High-Risk BCG-Unresponsive NMIBC with CIS (pdf)
SCSAUA 2025 – CORE-008 TIPS POSTER
Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvecin Patients with High-Risk NMIBC (pdf)
SCSAUA 2025 – PIVOT-006 TIPS POSTER
PIVOT-006 – A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for Intermediate-Risk NMIBC (pdf)
SCSAUA 2025 – BOND-003 COHORT P POSTER
BOND-003 Cohort P – A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary-Only, BCG-Unresponsive NMIBC (pdf)
SCSAUA 2025 – CRETO-EAP TIPS POSTER
Streamlined, Patient-Centric Design of the Cretostimogene Grenadenorepvec Expanded Access Program in Patients with NMIBC Unresponsive to BCG (pdf)
SCSAUA 2025 – ENROLLMENT CHARACTERISTICS BOND-003 & CORE-001
Enrollment Characteristics of Underrepresented Patients in Clinical Trials Using Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive NMIBC (pdf)
CUA 2025 CRETO-EAP MEETING POSTER
Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Unresponsive NMIBC with CIS (pdf)
AUA 2025 BOND-003 COHORT C LATE-BREAKING PLENARY
BOND-003 Cohort C- A Phase-3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive NMIBC with CIS (pdf)
AUA 2025 BOND-003 COHORT P LEARNING LAB
BOND-003 Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary-Only, BCG-Unresponsive NMIBC (pdf)
ASCO 2025 CORE-008 MEETING SLIDERS & POSTER
Updates to CORE-008: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with HR NMIBC (pdf)
AUA 2025 CORE-008 LEARNING LAB
Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer...
AUA 2025 PIVOT-006 LEARNING LAB
Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk NMIBC (pdf)
EAU 2025 TRANSLATIONAL CORRELATES USING URINARY MRD
Translational Correlates Using Urinary MRD to Assess Cretostimogene Grenadenorepvec: Analysis from the BOND-003 and CORE-001 Clinical Trials (pdf)
AUA 2025 TRANSLATIONAL CORRELATES USING URINARY MRD
Translational Correlates Using Minimal Residual Disease to Assess Cretostimogene Grenadenorepvec: Analysis from the BOND-003 and CORE-001 Clinical Trials (pdf)
EAU 2025 BOND-003 COHORT P TRIAL IN PROGRESS
BOND-003 Cohort P- A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-UR NMIBC (pdf)
EAU 2025 PIVOT-006 TRIAL IN PROGRESS
PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk NMIBC (pdf)
ASCO-GU 2025 MEETING SLIDES & POSTER
CORE-008- A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (pdf)
ASCO-GU 2025 MEETING SLIDES & POSTER
Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (pdf)
EAU 2025 LATE-BREAKING PRESENTATION
Updated Clinical & Translational Results from BOND003 Cohort C. A Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for HR BCG UR NMIBC with Carcinoma...
SESAUA 2025 PODIUM PRESENTATION
Encore Results: BOND-003 Cohort C- A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for HR BCG-UR with Carcinoma in Situ (pdf)
SUO 2024 TOPLINE RESULTS FROM BOND-003
BOND-003: Topline Results from BOND-003: A Phase-3 Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk BCG-Unresponsive NMIBC with CIS (pdf)
SUO 2024 MEETING POSTER
CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle Invasive Bladder Cancer...
SUO 2024 MEETING POSTER
The Cretostimogene Grenadenorepvec Expanded Access Program in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin​ (pdf)
SUO 2024 MEETING POSTER
BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (pdf)
SUO 2024 MEETING POSTER
PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer (pdf)
ASCO-GU 2024 POSTER AND MEETING PRESENTATION
PIVOT-006: A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk NMIBC Following TURBT (pdf)
ASCO 2024 POSTER AND MEETING PRESENTATION
Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-UR, High-Risk NMIBC with CIS (pdf)
NATURE MEDICINE 2024 PUBLICATION
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
AUA 2024 PIVOTAL RESULTS FROM BOND-003
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (pdf)
AUA 2024 BOND-003 Cohort P PRESENTATION
BOND-003 Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary-Only, BCG-Unresponsive NMIBC (pdf)
AUA 2024 PIVOT-006 PRESENTATION
PIVOT-006: A Phase-3, Randomized Study of Adjuvant lntravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk NMIBC (pdf)
SUO 2023 MEETING PRESENTATION
First Results from BOND-003: Phase 3 Study of Cretostimogene Grenadenorepvec Monotherapy for Patients with BCG-Unresponsive High-Risk NMIBC with CIS +/- Papillary (Ta/T1) Tumors (pdf)
MOLECULAR THERAPY 2006 PUBLICATION
52. A Phase 1 Dose-Escalation Trial of Intravesical cretostimogene grenadenorepvec for Superficial Transitional Cell Carcinoma (TCC) of the Bladder after Bacillus Calmette-Guerin (BCG) Failure: Molecular...
JOURNAL OF UROLOGY 2012 PUBLICATION
A first in human phase 1 study of cretostimogene grenadenorepvec, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer – PubMed...
AUA 2023 MEETING PRESENTATION
CORE-001, Phase 2 cretostimogene grenadenorepvec plus pembrolizumab combo in NMIBC demonstrated 85% (n=29/34) complete response at the initial 3-Month Timepoint (pdf)
SUO 2020 POSTER
BOND-003, Phase 3 cretostimogene grenadenorepvec monotherapy pivotal trial in BCG-unresponsive NMIBC (pdf)
SITC 2021 POSTER
BOND-003, Phase 3 cretostimogene grenadenorepvec monotherapy pivotal trial in BCG-unresponsive NMIBC (pdf)
SITC 2021 POSTER
CORE-001, Phase 2 cretostimogene grenadenorepvec plus pembrolizumab combo in NMIBC demonstrated 100% Complete Response Rate at 3 Months in 7 patients (pdf)
ASCO GU 2022 MEETING POSTER
BOND-003 A phase 3 study of cretostimogene grenadenorepvec in patients with NMIBC that is unresponsive to BCG (pdf)
AUA 2022 MEETING POSTER
CORE-001, Phase 2 study of cretostimogene grenadenorepvec in combination with pembrolizumab is well tolerated with encouraging efficacy (pdf)
ASCO 2022 MEETING POSTER
CORE-002, Phase 1b/2 cretostimogene grenadenorepvec plus nivolumab combo in MIBC demonstrated 54% Pathological Complete Response Rate (pdf)
ASCO 2022 MEETING POSTER
CORE-001, Phase 2 cretostimogene grenadenorepvec plus pembrolizumab combo in NMIBC demonstrated 92% Complete Response Rate at Any Time (pdf)
SITC 2022 MEETING POSTER
CORE-001, Phase 2 cretostimogene grenadenorepvec plus pembrolizumab combo in NMIBC demonstrated 88% (n=28/32) complete response at the initial 3-Month Timepoint (pdf)
FRONTIERS IN ONCOLOGY 2014 PUBLICATION
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity – PMC (nih.gov)
UROLOGIC ONCOLOGY 2017 PUBLICATION
An open label, single-arm, phase II multicenter study of the safety and efficacy of cretostimogene grenadenorepvec oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder...
CANCER THERAPY 2006 PUBLICATION
Cretostimogene grenadenorepvec, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer – PubMed (nih.gov)
CANCER RESEARCH 2006 PUBLICATION
Cretostimogene grenadenorepvec, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer – PubMed (nih.gov)
Want the latest news from CG Oncology?
Read NowRead Now

Disclaimer

This site is intended for attendees of the congress where the research is presented and limited to healthcare professionals (HCPs) in the market selected by each HCP. This site is for HCP personal educational use, and the content should not be further distributed.

This site contains scientific presentations on investigational products and/or investigational uses of approved products for CG Oncology sponsored studies. The safety and efficacy of these investigational products and/or investigational uses of approved products has not been established and there is no guarantee that such investigational products/uses will be filed with and/or approved for marketing by any health authority. Some presentations may be on approved products for approved uses. For some congresses, not all content presented at the congress may be posted due to congress rules.

Marketing authorization, approval status, and prescribing information for approved products varies by country. Please see information made available by the health authority in your country such as approved product labeling.